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Advanced cutaneous squamous cell carcinoma (cSCC) with nodal and/or distal metastases or large local 
spreading is inoperable and treatment options for patients are limited usually to chemotherapy and radiation. 
The National Comprehensive Cancer Network (NCCN) Guidelines® include some regimens of cisplatin 
(CDDP)-based systemic therapies, but no chemotherapy has yet been established for advanced cSCC1. 
Peplomycin sulfate, bleomycin, and irinotecan are licensed for cSCC in Japan, but are not commonly used in 
actual clinical practice because of their low efficacy and severe side effects, such as interstitial pneumonia, 
myelosuppression, and adverse digestive symptoms. CA regimen, the combination of CDDP and adriamycin 
(ADM), has been reported to show a response rate of about 60% for advanced cSCC2,3, whereas other regimens, 
such as CDDP plus 5-fluorouracil or CDDP plus cetuximab, have shown less than 20% response rate4. Suzuki 
et al.3 and Nakamura et al.5 previously reported a C’A’ regimen, modified from CA regimen, using carboplatin 
(CBDCA) and epirubicin (EPI). This regimen is preferable for elderly and patients with underlying disorders, 
because it reduces nephrotoxicity of CDDP and cardiac toxicity of ADM3. Nevertheless, as the number of 
reported cases treated with this regimen remains scant, further validation is required. Here, we report three 
cases of advanced cSCC treated with the combination of CBDCA and EPI. 
Clinical profiles of the patients are summarized in Table 1. They had a past history of burn scar, lichen 
sclerosus et atrophicus, and external injury, respectively. Patient case 3 was complicated with mild kidney 
failure. In all cases, primary cSCC lesions were surgically resected aiming for local control. The patients then 
received chemotherapies with an area under the curve (AUC) 5 dose of CBDCA and 60 mg/m2 of EPI, because 
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of the high-risk characteristics of the primary lesions mentioned in the NCCN Guidelines®, such as potential 
of nodal metastases or distal metastases. As the tumor of case 2 transformed into a granulocyte colony-
stimulating factor (G-CSF)-producing tumor and rapidly progressed shortly after the initial course of the 
chemotherapy, it was impossible for the patient to receive a second course. Patients in the other two cases 
received 4 courses of the regimen and their progression-free survival was 4 and 6 months, respectively. 
Neutropenia (over grade 3) was observed in every course in all cases.  
Although the risk of nodal metastases and distal metastases in cSCC is relatively low, currently licensed 
cSCC chemotherapies and radiation therapy are unsatisfactory in terms of both efficacy and safety. Two out 
of three cases treated with C’A’ regimen in this report achieved a progression-free period of several months 
without serious adverse events except for hematological toxicity. Notably, all three cases avoided death by 
C’A’ regimen in spite of their poor Eastern Cooperative Oncology Group (ECOG)-Performance Status (PS) 
(from Score 2 to 3), suggesting a good tolerability of this regimen. Further documentation of cases of cSCC 
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PFS, progression-free survival; OS, overall survival; M, male; F, female; LN, lymph node(s); PD, progressive 
disease; SD, stable disease 
* according to the Response Evaluation Criteria in Solid Tumours (RECIST) guideline version 1.1.  
(Eisenhauer E.A. et al. Eur J Cancer 45 (2009) 228-247) 
** according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events, version 
5.0. (https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50) 
 
 
 
 
 
 
 
 
